San Francisco startup Construction Therapeutics is likewise focusing on an oral, after-day-to-day GLP-1 drug identified as GSBR-1290—the drug surpassed Wall Road’s expectations in June any time a mid-phase review showed regular weight loss of all over 6% and it plans to start A further mid-phase trial towards the top of the calendar year—that